1. Volume 23, Issue 1, Pages 69-75 (February 2014)
High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in Luminal B HER2 negative and node-positive breast cancer 
Carmen Criscitiello, Davide Disalvatore, Michele De Laurentiis, Lucia Gelao, Luca Fumagalli, Marzia Locatelli, Vincenzo Bagnardi, Nicole Rotmensz, Angela Esposito, Ida Minchella, Sabino De Placido, Michele Santangelo, Giuseppe Viale, Aron Goldhirsch, Giuseppe Curigliano 
The Breast 
Volume 23, Issue 1, Pages (February 2014)
DOI: /j.breast
Copyright © 2013 Elsevier Ltd Terms and Conditions

2. Fig. 1
Distribution of Propensity Scores values, by adjuvant treatment group. Dark gray bars indicate patients selected in the matched analysis, light gray bars indicate unmatched patients.
The Breast  , 69-75DOI: ( /j.breast )
Copyright © 2013 Elsevier Ltd Terms and Conditions

3. Fig. 2
Overall survival (panel A), Disease-free survival (panel B), in the 598 matched patients, by systemic treatments. Univariate log-rank test p-values is reported.
The Breast  , 69-75DOI: ( /j.breast )
Copyright © 2013 Elsevier Ltd Terms and Conditions

4. Fig. 3
Subpopulation treatment Effect Pattern plot (STEPP) of 5-year Disease-free survival. The rug plots placed at the top and bottom of the graph show the Ki-67 values in patients that relapsed (top) and in those who did not relapse (bottom) (panel A).Disease-free survival in the low Ki-67 (Ki-67 < 32) group according to systemic treatment (panel B). Disease-free survival in the high Ki-67 (Ki-67 ≥ 32) group according to systemic treatment (panel C). Univariate log-rank test p-values and Hazard Ratios (HR) (HT/CT vs HT) adjusted for age, primary tumor size, tumor grade, ER, PgR, PVI and type of surgery are reported.
The Breast  , 69-75DOI: ( /j.breast )
Copyright © 2013 Elsevier Ltd Terms and Conditions